RSS Parrot

IT Security Incident at Novo Nordisk Learn more in the press release here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916571

https://nitter.poast.org/novonordisk/status/2065095087567130795#m

Published: June 11, 2026 15:33

IT Security Incident at Novo Nordisk Learn more in the press release here: novonordisk.com/news-and-med…

#PRESS: Results from our phase 3 trials presented at the ADA Scientific Sessions showed that our first amylin-based investigational treatment for metabolic diseases shows promising, consistent reductions in blood sugar and weight across various stages of type 2 diabetes. With these findings, the investigational treatment has the potential to be a first-in-class amylin and GLP-1 combination therapy for people with type 2 diabetes. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916567

https://nitter.poast.org/novonordisk/status/2063736116092748140#m

Published: June 7, 2026 21:33

#PRESS: Results from our phase 3 trials presented at the ADA Scientific Sessions showed that our first amylin-based investigational treatment for metabolic diseases shows promising, consistent reductions in blood sugar and weight across various stages of…

Pinned: #PRESS: Prescriptions of our obesity pill surpass 3 million since launch. The majority of new pill prescriptions are for people new to GLP-1 therapy, bringing obesity medicine to many previously untreated. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916566

https://nitter.poast.org/novonordisk/status/2063615366320795801#m

Published: June 7, 2026 13:33

#PRESS: Prescriptions of our obesity pill surpass 3 million since launch. The majority of new pill prescriptions are for people new to GLP-1 therapy, bringing obesity medicine to many previously untreated. Learn more in the press release here:…

#PRESS: We’re presenting new analyses at the ADA 2026 Scientific Sessions, exploring our obesity treatment’s impact across a wide range of obesity-related and cardiometabolic conditions. Findings from four different trials examine outcomes in obstructive sleep apnea, asthma-related adverse events, cardiometabolic risk factors, and other weight-related complications. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916563

https://nitter.poast.org/novonordisk/status/2063306947881799999#m

Published: June 6, 2026 17:08

#PRESS: We’re presenting new analyses at the ADA 2026 Scientific Sessions, exploring our obesity treatment’s impact across a wide range of obesity-related and cardiometabolic conditions. Findings from four different trials examine outcomes in obstructive…

#PRESS: New real-world evidence presented at the ADA Scientific Sessions suggests adults with type 2 diabetes who escalated to an available higher once-weekly injectable semaglutide dose were as likely to achieve blood sugar goals and more likely to achieve meaningful weight loss compared to switching to another therapy.   Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916561

https://nitter.poast.org/novonordisk/status/2063246771891929154#m

Published: June 6, 2026 13:08

#PRESS: New real-world evidence presented at the ADA Scientific Sessions suggests adults with type 2 diabetes who escalated to an available higher once-weekly injectable semaglutide dose were as likely to achieve blood sugar goals and more likely to…

We are presenting phase two clinical data at the ADA Scientific Sessions showcasing investigational zenagamtide's ability to significantly reduce blood sugar and body weight in adults with type 2 diabetes. Based on these results, zenagamtide will advance into phase three clinical trials. Learn more in the press release here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916559

https://nitter.poast.org/novonordisk/status/2063042152624521712#m

Published: June 5, 2026 23:35

We are presenting phase two clinical data at the ADA Scientific Sessions showcasing investigational zenagamtide's ability to significantly reduce blood sugar and body weight in adults with type 2 diabetes. Based on these results, zenagamtide will advance…

#PRESS: Our GLP-1 pill for the treatment of overweight or obesity launches in the United Arab Emirates as we expand global access to obesity care. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916558

https://nitter.poast.org/novonordisk/status/2062052542570193130#m

Published: June 3, 2026 06:03

#PRESS: Our GLP-1 pill for the treatment of overweight or obesity launches in the United Arab Emirates as we expand global access to obesity care. Learn more in the press release here: novonordisk.com/content/nnco…

#PRESS: New data from our cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916555

https://nitter.poast.org/novonordisk/status/2059626876302205067#m

Published: May 27, 2026 13:24

#PRESS: New data from our cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans. From amylin-based pipeline candidates to continued…

We’re presenting new findings from our real-world-evidence study, POSEIDON, at the European Atherosclerosis Society (EAS) Congress. Our landmark study shows that 2 in 5 people with heart disease have CV inflammation, which increases the risk of heart attack or stroke. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916553

https://nitter.poast.org/novonordisk/status/2059194364576891364#m

Published: May 26, 2026 08:46

We’re presenting new findings from our real-world-evidence study, POSEIDON, at the European Atherosclerosis Society (EAS) Congress. Our landmark study shows that 2 in 5 people with heart disease have CV inflammation, which increases the risk of heart…

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) recommends EU approval of our high-dose obesity injection in a single-dose pen, providing up to 20.7% mean weight loss. Learn more in our company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916552

https://nitter.poast.org/novonordisk/status/2057878119545999524#m

Published: May 22, 2026 17:35

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) recommends EU approval of our high-dose obesity injection in a single-dose pen, providing up to 20.7% mean weight loss. Learn more in our company announcement here:…

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of our GLP-1 pill for the treatment of obesity in the European Union (EU), making it one step closer to becoming available for people with overweight or obesity in the EU. Learn more in our company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916551

https://nitter.poast.org/novonordisk/status/2057812104329986277#m

Published: May 22, 2026 13:13

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of our GLP-1 pill for the treatment of obesity in the European Union (EU), making it one step closer to becoming available for people with overweight or obesity in…

#PRESS We are presenting 14 new abstracts on MASH treatment at the European Association for the Study of the Liver Congress (EASL) taking place 27-30 May. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916550

https://nitter.poast.org/novonordisk/status/2056708023372898388#m

Published: May 19, 2026 12:06

#PRESS We are presenting 14 new abstracts on MASH treatment at the European Association for the Study of the Liver Congress (EASL) taking place 27-30 May. Learn more in the press release here: novonordisk.com/content/nnco…

#PRESS Oral semaglutide for obesity has demonstrated 21.6% weight loss in early responders. Separately, users reported improved physical function. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916548

https://nitter.poast.org/novonordisk/status/2054443062693134726#m

Published: May 13, 2026 06:06

#PRESS Oral semaglutide for obesity has demonstrated 21.6% weight loss in early responders. Separately, users reported improved physical function. Learn more in the press release here: novonordisk.com/content/nnco…

#PRESS Our new data presented at the European Congress on Obesity highlights the powerful, consistent weight loss that our obesity injection delivers for women across all menopause stages. The data reveals that it also lowers risk of migraine, depression and cardiovascular disease, highlighting the broad support our medicine provides for women living with obesity. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916546

https://nitter.poast.org/novonordisk/status/2054147850737508698#m

Published: May 12, 2026 10:33

#PRESS Our new data presented at the European Congress on Obesity highlights the powerful, consistent weight loss that our obesity injection delivers for women across all menopause stages. The data reveals that it also lowers risk of migraine, depression…

#PRESS Our high-dose obesity injection delivers nearly 28% weight loss in early responders. The majority of weight lost with our injection was driven by reductions in fat mass. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916545

https://nitter.poast.org/novonordisk/status/2054081478728851546#m

Published: May 12, 2026 06:09

#PRESS Our high-dose obesity injection delivers nearly 28% weight loss in early responders. The majority of weight lost with our injection was driven by reductions in fat mass. Learn more in the press release here: novonordisk.com/content/nnco…

#PRESS: Our quarterly results are out! We're off to a good start to 2026 with exciting momentum across our pipeline. Hear our CEO Mike Doustdar reflect on our results - and read more in the company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916542

https://nitter.poast.org/novonordisk/status/2051898667108298982#m

Published: May 6, 2026 05:35

#PRESS: Our quarterly results are out! We're off to a good start to 2026 with exciting momentum across our pipeline. Hear our CEO Mike Doustdar reflect on our results - and read more in the company announcement here: novonordisk.com/content/nnco… Video

#PRESS The New England Journal of Medicine just published our phase 3 data on denecimig (Mim8), demonstrating significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, compared to those who received prior clotting factor prophylaxis treatment during the run-in phase or on-demand treatment. Learn more in our press release here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916538

https://nitter.poast.org/novonordisk/status/2049597041785946466#m

Published: April 29, 2026 21:09

#PRESS The New England Journal of Medicine just published our phase 3 data on denecimig (Mim8), demonstrating significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, compared to those who received prior…

#PRESS We are presenting 52 new abstracts on obesity treatment at the European Congress on Obesity in Istanbul, Türkiye from 12–15 May. Learn more in the press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916537

https://nitter.poast.org/novonordisk/status/2049098133724909987#m

Published: April 28, 2026 12:07

#PRESS We are presenting 52 new abstracts on obesity treatment at the European Congress on Obesity in Istanbul, Türkiye from 12–15 May. Learn more in the press release here: novonordisk.com/content/nnco…

#PRESS Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes. Learn more in our press release here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916535

https://nitter.poast.org/novonordisk/status/2047243248238743811#m

Published: April 23, 2026 09:16

#PRESS Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes. Learn more in our press release here: novonordisk.com/content/nnco…